DYN
Dyne Therapeutics, Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers):
holder breadth -16.7% ·
share flow -19.4% ·
net new positions -20.0%
— formula
Broad distribution — falling shares and fewer holders
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 86 | +1 | 73.72M | $1.63B | +7 | −5 |
| Q1 2026 | 87 | -4 | 78.51M | $1.42B | +7 | −12 |
| Q4 2025 | 92 | 0 | 87.58M | $1.71B | +2 | −1 |
| Q3 2025 | 18 | +1 | 57.06M | $721.88M | +1 | −1 |
| Q2 2025 | 15 | +2 | 34.50M | $328.45M | +2 | — |
| Q1 2025 | 10 | -1 | 12.46M | $130.33M | +1 | −2 |
| Q4 2024 | 11 | 0 | 14.93M | $351.71M | +1 | −1 |
| Q3 2024 | 10 | -2 | 10.58M | $380.14M | +1 | −3 |
| Q2 2024 | 12 | — | 13.13M | $463.42M | — | — |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Citadel Advisors ✦ | 2.94M | -31.9% | $105.58M | 0.1% | ▼ Trim | 2 | SEC ↗ |
| 2 | T. Rowe Price ✦ | 2.64M | +11.4% | $94.70M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 2.64M | +11.4% | $94.70M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Adage Capital Partners ✦ | 2.40M | -27.8% | $86.31M | 0.2% | ▼ Trim | 2 | SEC ↗ |
| 5 | Geode Capital Management ✦ (passive) | 1.86M | +4.8% | $66.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 6 | Geode Capital Management ✦ (passive) | 1.86M | +4.8% | $66.80M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 7 | Norges Bank ✦ (passive) | 432.33K | +303.7% | $15.53M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 8 | Point72 Asset Management ✦ | 102.48K | -71.3% | $3.68M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 9 | AQR Capital Management ✦ | 89.20K | +950.0% | $3.20M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 10 | AQR Capital Management ✦ | 89.20K | +950.0% | $3.20M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | AQR Capital Management ✦ | 89.20K | +950.0% | $3.20M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | D. E. Shaw & Co. ✦ | 73.04K | -17.4% | $2.62M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | Wellington Management ✦ | 41.66K | -81.6% | $1.50M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 14 | Wellington Management ✦ | 41.66K | -81.6% | $1.50M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 15 | Wellington Management ✦ | 41.66K | -81.6% | $1.50M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 16 | Wellington Management ✦ | 41.66K | -81.6% | $1.50M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 17 | Millennium Management ✦ | 5.99K | New | $215,197 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Millennium Management | $215,197 | 0.0% |
Exited
| Marshall Wace | $9.65M | was 0.0% |
| Two Sigma Investments | $5.62M | was 0.0% |
| Renaissance Technologies | $4.45M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 226 holders, 184.59M shares, $2.74B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Director · 1.36M sh · $33.99M
Director · 478.38K sh · $11.96M
Director · 322.46K sh · $8.06M
Director · 63.64K sh · $1.67M
Officer · 1.80K sh · $47,225
Officer · 1.56K sh · $40,892
Officer, Director · 4.99K sh · $131,032
Officer · 226 sh · $5,939
Director · 268.35K sh · $7.03M
Director · 94.42K sh · $2.47M
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology